Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1]. Core Insights - The report is optimistic about the trend of innovative drugs, particularly focusing on the upcoming ESMO conference and national medical insurance negotiations [1][3]. - The innovative drug sector is expected to experience a qualitative change driven by quantitative growth over the next 5-10 years, with business development (BD) overseas, continuous data catalysts, and new product sales driving the rise of innovative drugs [3]. Summary by Sections 1. Innovative Drug Highlights - uniQure's gene therapy AMT-130 for Huntington's disease showed significant results in a key I/II clinical trial, with a 75% reduction in disease progression at high doses [3][5]. - Novartis acquired Akero Therapeutics for $5.2 billion, focusing on FGF21-targeted therapies for MASH, with the core asset being efruxifermin, currently in Phase III trials [22][23]. - The report emphasizes the importance of clinical data from the upcoming ESMO conference and the third-quarter earnings reports, as well as the November national medical insurance negotiations [3]. 2. Industry Catalysts and Strategies - The report suggests focusing on companies with strong clinical data, commercialization capabilities, and potential for successful international expansion, recommending specific companies in both the Biopharma and Pharma sectors [3]. - Suggested companies include: - Pharma: CSPC Pharmaceutical Group, China Biologic Products, and Hengrui Medicine [3]. - Biopharma: Innovent Biologics, Kelun-Biotech, and Zai Lab [3]. 3. Investment Recommendations - The report recommends a dual focus on Biotech and generic-to-innovative companies with potential catalysts, highlighting specific companies in each category [3]. - Suggested Biotech companies include: EdiGene, CanSino Biologics, and I-Mab Biopharma [3]. - Suggested generic-to-innovative companies include: Jingxin Pharmaceutical, Enhua Pharmaceutical, and Changchun High-tech [3].

Investment Rating - The industry rating is "Outperform the Market" [6] Core Insights - The report highlights that the construction materials sector is expected to benefit from supply-side reforms and a potential recovery in housing demand due to declining interest rates and supportive government policies aimed at stabilizing the real estate market [2][4][10] - The report notes that the cumulative completion of energy-saving renovations for existing buildings during the 14th Five-Year Plan period is projected to reach 800 million square meters, indicating a strong focus on quality construction standards [2][10] - The report emphasizes that the market is becoming increasingly sensitive to policy easing, with the real estate sector entering a bottoming phase after three consecutive years of decline in sales area [2][10] Summary by Sections Investment Recommendations - The report suggests focusing on three main investment lines: 1. High-quality companies benefiting from stock renovations, such as Weixing New Materials, Beixin Building Materials, and Tubao [4] 2. Undervalued stocks with long-term alpha attributes, such as Sankeshu, Dongfang Yuhong, and Jianlang Hardware [4] 3. Leading cyclical building material companies showing signs of bottoming, including Huaxin Cement, Conch Cement, China Jushi, and Qibin Group [4] Recent High-Frequency Data - As of October 10, 2025, the national average price of bulk P.O 42.5 cement is 346.8 CNY/ton, showing a month-on-month increase of 1.2% but a year-on-year decrease of 11.7% [11] - The national average price of glass (5.00mm) is 1265.7 CNY/ton, reflecting a month-on-month increase of 8.7% and a year-on-year increase of 2.1% [19][21] Sector Performance - The construction materials index increased by 2.66%, with sub-sectors such as cement manufacturing (+5.36%) and other building materials (+3.05%) showing strong performance [51]

- The report introduces a **PCR timing strategy** based on the **Put/Call Ratio (PCR)**, which is a market sentiment indicator. The strategy logic includes trend-following (PCR rising indicates positive sentiment) and counter-trend (low PCR suggests a sentiment bottom with potential reversal) [5][66][73] - The **PCR timing strategy** is applied to **Shanghai Stock Exchange 50 (SSE 50)** and **CSI 300** indices. The strategy's performance is tracked, showing a year-to-date return of 0.09% for CSI 300, with the latest signal being "no position" (signal 0) [5][73][83] - The **PCR timing strategy** performance metrics for CSI 300 include annualized volatility (15.31%), maximum drawdown (9.44%), Sharpe ratio (0.25), and Calmar ratio (0.43) for 2025. The overall performance from 2020 to 2025 shows an annualized return of 19.96%, maximum drawdown of 23.42%, and Sharpe ratio of 1 [79] - For SSE 50, the **PCR timing strategy** metrics for 2025 include annualized volatility (13.46%), maximum drawdown (12.59%), Sharpe ratio (-0.24), and Calmar ratio (-0.2). The overall performance from 2017 to 2025 shows an annualized return of 14.06%, maximum drawdown of 24.96%, and Sharpe ratio of 0.75 [80]

Export Performance - In September, China's exports rebounded significantly, with a year-on-year increase of 8.3%, up 3.9 percentage points from August, attributed mainly to a low base effect[2] - Exports to the US, EU, and UK improved by 6.1, 3.8, and 2.0 percentage points respectively, although exports to ASEAN dropped by 6.9 percentage points to 15.6%[3] - The contribution of capital goods exports to overall export improvement rose by 2.1 percentage points, driven by the US's accelerated reconstruction of domestic capacity[4] Import Trends - Imports in September saw a year-on-year increase of 7.4%, marking the highest monthly growth rate of the year, with a significant rise in capital goods imports by 13.8%[4] - The trade surplus narrowed slightly to $90.45 billion due to the simultaneous increase in imports[2] Trade Relations and Risks - The ongoing uncertainty in US-China trade relations, including threats of additional tariffs and export controls, remains a critical variable affecting future export performance[2] - The imposition of a 40% tariff on transshipment goods by the US has already impacted exports to ASEAN, indicating potential future challenges[5] - The report highlights the need for close monitoring of US-China negotiations, especially with a key date of November 1 approaching, which may accelerate discussions[5]

Export Performance - In September, China's exports rebounded significantly, with a year-on-year increase of 8.3%, up 3.9 percentage points from August, attributed mainly to a low base effect[2] - Exports to the US, EU, and UK improved by 6.1, 3.8, and 2.0 percentage points respectively, although exports to ASEAN dropped by 6.9 percentage points to 15.6%[3] - Key export categories showed strong performance, particularly in capital goods, which contributed 2.1 percentage points to the overall export improvement[4] Import Trends - Imports in September saw a year-on-year increase of 7.4%, marking the highest monthly growth rate of the year, driven by a significant narrowing of declines in commodities like crude oil and soybeans[5] - Capital goods imports surged by 13.8% year-on-year, contributing to the overall import growth[5] Trade Balance - The trade surplus slightly narrowed to $90.45 billion in September due to the simultaneous increase in both exports and imports[2] Economic Outlook - The ongoing uncertainties in US-China trade relations, including potential new tariffs and export controls, remain critical factors influencing future export performance[6] - Despite the challenges, there is a possibility of reaching a mutually acceptable long-term agreement between the US and China, as both sides appear to be preparing for more serious negotiations[6] Risk Factors - Increased global trade policy uncertainties could lead to lower-than-expected export growth, posing risks to the overall economic outlook[7]

Group 1 - The report highlights that U.S. stocks experienced significant declines on "Black Friday" due to comments from Trump regarding tariffs on China, which may lead to a cycle of "threat-negotiation-exemption" [1][7] - The Federal Reserve officials expressed concerns about the labor market, with expectations of potential interest rate cuts increasing, particularly a 25 basis point cut in October [1][8] - The report emphasizes the importance of monitoring U.S.-China tariff negotiations and the impact of government shutdowns on data releases, while suggesting a favorable outlook for gold as a safe-haven asset [1][7] Group 2 - The report indicates mixed performance in global equity markets, with the Nikkei 225 showing the highest increase of 5.07%, while the Hang Seng Index and Dow Jones Industrial Average saw declines of 3.13% and 2.73%, respectively [2][29] - In the commodities market, COMEX silver and gold saw increases of 2.75% and 2.68%, respectively, while NYMEX light crude oil experienced a significant drop of 4.04% [24][43] - The report notes that the U.S. labor market remains a concern, with initial jobless claims data not being released due to the government shutdown, highlighting the uncertainty in economic indicators [8][29]

Group 1: Core Insights - The report indicates that the performance of equity-type and mixed-type fixed income plus funds has been volatile this year, with a positive performance in September, where mixed, equity, and convertible bond funds increased by 0.87%, 0.77%, and 0.15% respectively [3][14]. - The report highlights a continuous reduction in the position of convertible bond products after a prolonged period of steady growth, indicating a phase of adjustment [4][14]. - The overall risk exposure of fixed income plus funds in terms of bond duration remains stable, while there is an increase in the use of credit strategies, particularly with a notable rise in growth style exposure in equity assets [5][19][21]. Group 2: Fixed Income Plus Fund Tracking - The report outlines that a quarterly selection of 10 funds based on various metrics has been made to construct a preferred fixed income plus fund portfolio, which has outperformed the secondary bond fund index by 0.34% this year [6][27]. - The preferred portfolio's performance in September showed a slight underperformance against the secondary bond fund index by 0.22%, indicating a more stable performance overall [27]. - The report provides detailed tracking of the preferred portfolio's holdings, showcasing a diverse range of asset types and equity classifications [33][35]. Group 3: Pure Bond Fund Tracking - The pure bond fund index experienced a decline of 0.15% in September, with a year-to-date return of 0.29%, while the short-term pure bond fund index increased by 0.03% with a year-to-date increase of 0.93% [39]. - The report notes a significant adjustment in credit structure exposure for pure bond funds, with a general increase in credit bond allocation, reflecting a strong consistency in credit strategy adjustments [44]. - The preferred pure bond fund portfolio has also outperformed the medium to long-term pure bond fund index, with a slight outperformance of 0.01% in September and 0.07% year-to-date [50][56].

Group 1 - The report highlights the re-emergence of the trade war between the US and China, with the US imposing a 100% tariff on Chinese products starting November 1, 2025, and implementing export controls on key software [2][7] - The ongoing trade conflict is seen as a continuation of the trade barriers established since April 2025, which have not been resolved despite multiple rounds of negotiations [2][8][11] - The potential for a spiral escalation in trade tensions is noted, with both sides likely to continue retaliatory measures, impacting various sectors beyond trade [2][12] Group 2 - Short-term market impacts are expected to be manageable, as the A-share market rebounded quickly after previous trade war shocks, indicating investor resilience and experience [2][13] - In the medium term, structural investment opportunities are anticipated, particularly in sectors benefiting from import substitution and potential domestic policy easing [2][13] - Investment recommendations include increasing allocations to defensive sectors such as utilities and banks in the short term, while focusing on strategic technology sectors like nuclear fusion, AI, and semiconductor manufacturing for medium-term opportunities [3][13]

策略定期研究 2025 年 10 月 12 日 策 略 研 究 无需悲观，以我为主——对特朗普关税风波再起 的思考 投资要点： 特朗普关税风波再起，无需悲观、以我为主。 策 略 定 在 4 月"对等关税"冲击后，特朗普于 10 月 10 日再次在社交媒体上 释放出关税威胁。在此消息发布后海外市场反应迅速，美国股市、欧洲股 市、美元指数、原油、铜均走低，仅黄金和白银上涨、美债收益率下跌。 这不由得让市场联想到 4 月"对等关税"引发的"巨震"，有必要思考后 续的应对策略。 期 报 告 （1）近期中美之间发生了什么？近期（10 月以来）美国"小动作" 不断：包括对中国船舶征收"港口费"、将多家中国实体列入出口管制"实 体清单"、威胁要禁止中国航司在执飞往返美国的航班时飞越俄罗斯领空。 我国迅速采取反制措施：10 月 9 日商务部连续发布公告，对稀土、锂电池、 超硬材料等多项物项实施出口管制，将 14 家外国实体列入不可靠实体清 单。10 月 10 日我方发布对高通进行反垄断调查、对涉美船舶收取船舶特 别港务费的公告。最终在美东时间 10 月 10 日，特朗普在社交媒体上发布 长文释放关税威胁，再度引起全球资产动荡 ...

Investment Rating - The report maintains an "Outperform" rating for the light industry manufacturing sector, indicating a positive outlook compared to the broader market [2]. Core Insights - The report highlights the resilience of defensive assets and manufacturers with overseas production capabilities amid fluctuations in the trade environment between China and the U.S. Recommended stocks include Meiyingsen, Yutong Technology, and Yongxin Co., with a focus on companies like Jiangxin Home and Aopu Technology [1][5]. - The light industry manufacturing sector is expected to see a steady performance in Q3, with leading companies in personal care maintaining stable operations and overseas manufacturers strengthening their competitive edge [1][5]. Summary by Sections Light Industry Manufacturing - The light industry manufacturing index increased by 0.71% from October 8 to October 10, 2025, outperforming the CSI 300 index, which decreased by 0.51% [11]. - Key companies expected to perform well include Meiyingsen (projected Q3 net profit growth of 20%-30%), Yutong Technology (5%-15%), and Yongxin Co. (0%-10%) [6][7]. Home Furnishing - The home furnishing sector is experiencing pressure, with a notable bankruptcy in the custom home industry reflecting challenges for smaller firms. However, leading companies are expected to gain market share as demand stabilizes [5][6]. - The report suggests a left-side investment opportunity in home furnishing stocks, particularly those with high dividend yields [5]. Paper and Packaging - The report notes a mixed performance in the paper and packaging sector, with prices for various paper types showing fluctuations. For instance, double glue paper prices decreased by 50 RMB/ton, while corrugated paper prices increased by 65.62 RMB/ton [37]. - The overall revenue for the paper and paper products industry saw a decline of 1.9% year-on-year from January to August 2025, indicating a challenging environment [46][48]. Consumer Goods - The consumer goods segment is expected to benefit from a strong Q4, with companies like Zhengkang Oral Care and Mingyue Lens projected to see revenue growth of 10%-20% and 0%-10%, respectively [6]. - The report emphasizes the potential for growth in the personal care sector, particularly with brands expanding their marketing channels [6]. Export Chain - The report discusses the impact of U.S. tariffs on imported furniture and cabinetry, which may benefit companies with established overseas production capabilities [6]. - Companies like Zhongxin Co. and Jiangxin Home are highlighted as key players in the export chain, with expected net profit declines of 20%-10% for Q3 [6]. Cost Tracking - The report provides insights into cost trends, noting a decrease in shipping costs and fluctuations in raw material prices, which could impact overall profitability in the sector [33][40].